TY  - CHAP
AU  - Dominic Magirr
ED  - John W. Cassidy
ED  - Belle Taylor
Y1  - 2020-09-09
PY  - 2020
T1  - Efficacy Evaluation in the Era of Precision Medicine: The Scope for AI
N2  - There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic burden of cancer increases, the current paradigm in drug development is unsustainable. In this book, we discuss the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. We consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence.
BT  - Artificial Intelligence in Oncology Drug Discovery and Development
SP  - Ch. 6
UR  - https://doi.org/10.5772/intechopen.90455
DO  - 10.5772/intechopen.90455
SN  - 978-1-78985-897-6
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-25
ER  -